Due to change of priority for Nestle Health Science (Il Sole 24 Ore Radiocor) - Paris, 04 Jun - Valbiotis, a French scientific research laboratory specialized in the development and marketing of dietary supplements, said that it has reached an agreement with Nestle Health Science to terminate the licensing and supply agreement binding the two companies.

The agreement provides Valbiotis with full ownership of the Totum.63 intellectual property rights, giving it full strategic control over the active substance, which has been clinically approved for use in the treatment of diabetes.

In February 2020, Valbiotis and Nestle Health Science entered into a global contract including a worldwide license agreement granting the Swiss group exclusive commercial rights to Totum.63.

"Following changes at Nestle Health Science and the company's shift in priorities in the health nutrition market, Valbiotis and Nestle Health Science have come to an agreement to terminate this global contract," Valbiotis said in a statement.

The agreement excludes any reimbursement of payments made to Valbiotis by Nestle Health Science. The payments total 12.75 million Swiss francs since February 2020, have been used to finance the final phases of the Totum.63 clinical program.

"This process was brought to a successful conclusion in 2023 with the positive results of the Phase II/III REVERSE-IT study, followed by the mode of action study," Valbiotis said.

The results establish Totum.63 as "the first plant-based non-drug active substance with such strong scientific evidence for the management of prediabetes and the early stages of type 2 diabetes," it added.

Valbiotis will have total freedom to choose future licensing partners for Totum.63.

AAA-Web

(RADIOCOR) 04-06-24 12:38:41 (0320) 5 NNNN